Skip to content

The Oslo Acute Reperfusion Stroke Study (OSCAR)

The Oslo Acute Reperfusion Stroke Study (OSCAR)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06220981
Acronym
OSCAR
Enrollment
1500
Registered
2024-01-24
Start date
2017-01-10
Completion date
2025-12-31
Last updated
2024-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Brief summary

Prospective registry of clinical and radiological data in acute ischemic stroke patients after endovascular treatment.

Interventions

OTHEREndovascular treatment

Sponsors

Oslo University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Age 18 years or older * Patients with ischemic stroke and cerebral arterial occlusion treated with endovascular revascularization. * All stroke severities and vascular distributions are eligible. * Informed written consent signed by the patient, verbal consent from the patient as witnessed by a non-participating health care person or consent by the signature of the patient's family must be provided before inclusion. Patients for whom no informed consent can be obtained will not be included in the study but will be treated according to standard guidelines.

Exclusion criteria

• Patient not eligible for the study or not available for follow-up assessments (e.g. non- resident).

Design outcomes

Primary

MeasureTime frameDescription
Modified Rankin Scale Score3 monthsModified Rankin Scale Score (mRS), min 0, max 6

Secondary

MeasureTime frameDescription
Infarct volume1 dayInfarct volume (ml)
National Institute of Health Stroke Scale ScoredischargeNational Institute of Health Stroke Scale Score (NIHSS, min 0, max 42)
Death due to any cause3 monthsMortality
Volume of new areas of diffusion restriction1 dayVolume of new areas of diffusion restriction
serious adverse events3 monthsserious adverse events
Incidence of symptomatic intracranial hemorrhage1 dayIncidence of symptomatic intracranial hemorrhage (SICH)

Countries

Norway

Contacts

Primary ContactAnne Hege Aamodt
anne.hege.aamodt@gmail.com97417734
Backup ContactBrian Enriquez
brienr@ous-hf.no

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026